Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/18/2025

Management of Headaches in Adults with Comorbid Autism and ADHD

Medication Considerations

  • The American Academy of Neurology recommends considering atomoxetine as a first-line non-stimulant option for ADHD in adults with comorbid autism, due to its efficacy and fewer cardiovascular side effects compared to stimulants 2
  • Clonidine alone is associated with potential adverse effects including somnolence, fatigue, irritability, insomnia, nightmares, dry mouth, sedation, bradycardia, and syncope, and should be used cautiously 1
  • Non-stimulants like atomoxetine provide "around-the-clock" effects without the rebound/crash experienced with stimulants, and may be better tolerated in patients experiencing stimulant side effects 3, 2

Dosing and Administration

  • For atomoxetine, start with a lower dose and gradually titrate upward, with a daily dose that can be split into two equal doses administered in the morning and evening to reduce adverse effects 1, 3
  • Set appropriate expectations regarding delayed onset of action (6-12 weeks for full effect) when using atomoxetine 1, 2
  • If continuing Clonidine, the recommended starting dose is 0.1 mg tablet at bedtime, which can be increased to twice-daily administration, with a maximum recommended dose of 0.4 mg/day 1

Monitoring and Follow-up

  • Monitor vital signs, particularly blood pressure and heart rate, at each follow-up visit when using atomoxetine or Clonidine 1
  • Assess for common side effects of atomoxetine including decreased appetite, headache, stomach pain, nausea, dry mouth, and insomnia 2
  • Regular reassessment of treatment efficacy for both ADHD and autism symptoms is essential when using atomoxetine or Clonidine 2